Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition.

about

Neuroprotection with hypothermia and allopurinol in an animal model of hypoxic-ischemic injury: Is it a gender question?

P2860

Q42361461-980A17A0-9626-4E7A-B517-3CAB4531E973

P2860

Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition.

Item

http://www.wikidata.org/entity/Q38762849

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Discovery of Novel Allopurinol ...... d Xanthine Oxidase Inhibition.

@en

type

Item

label

Discovery of Novel Allopurinol ...... d Xanthine Oxidase Inhibition.

@en

prefLabel

Discovery of Novel Allopurinol ...... d Xanthine Oxidase Inhibition.

@en

P1476

Discovery of Novel Allopurinol ...... ed Xanthine Oxidase Inhibition

@en

P2093

Cai-Hu Li

http://www.w3.org/2001/XMLSchema#string

Guangdi Wang

http://www.w3.org/2001/XMLSchema#string

Lin Dong

http://www.w3.org/2001/XMLSchema#string

Qiu Zhong

http://www.w3.org/2001/XMLSchema#string

Shanchun Guo

http://www.w3.org/2001/XMLSchema#string

Ting-Ting Cao

http://www.w3.org/2001/XMLSchema#string

Ying Li

http://www.w3.org/2001/XMLSchema#string

Yong Li

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol

Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.

Tanespimycin as antitumor therapy.

Development of purine-scaffold small molecule inhibitors of Hsp90.

Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.

Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers.

SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.

Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.

Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies.

CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo.

P31

scholarly article

P356

10.3390/MOLECULES21060771

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shilong Zheng

Shu-Fan Yin

P577

2016-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27331805

http://www.w3.org/2001/XMLSchema#string

P932

5538589

http://www.w3.org/2001/XMLSchema#string

Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition.

about

P2860

P2860

Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P932